Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

EU demands immediate access to UK-made vaccines in AstraZeneca legal battle

Stock MarketsApr 28, 2021 06:45AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp

By Francesco Guarascio

BRUSSELS (Reuters) -European Union lawyers on Wednesday demanded AstraZeneca (NASDAQ:AZN) immediately deliver COVID-19 vaccines from its factories in Britain, in a move that risks reigniting a spat with London over scarce vaccine supplies.

The call came in the opening hearing of the European Commission's legal case in Brussels against the Anglo-Swedish drugmaker over supply delays.

AstraZeneca has missed delivery targets to both Britain and the EU, delaying the bloc's immunisation campaign in particular, and stoking tensions between London and Brussels.

The bloc accuses the company of failing to meet its contractual obligations, whereas AstraZeneca says it is complying with the agreement, which it considers not fully binding.

"We demand deliveries by the end of June and we also demand with immediate effect the use of all plants listed in the contract," EU lawyer Rafael Jafferali told the judge in a hearing room packed with journalists.

"The contract listed a series of plants that had to be used by AstraZeneca and that still today, in breach of the contract, AstraZeneca is not using," the lawyer said.

AstraZeneca lawyer Hakim Boularbah retorted: "There is no obligation to use the factories."

The contract lists four vaccine-making plants, with two of them Britain. Whereas AstraZeneca has delivered doses to the EU from sites in Belgium and the Netherlands, it has not shipped to EU countries any dose produced in UK plants run by Oxford Biomedica and Cobra Biologics.

The contract also says that a Catalent (NYSE:CTLT) factory in the United States which manufactures AstraZeneca jabs "may serve as a back-up supply site".

EU officials have told Reuters that AstraZeneca justifies the lack of supplies from Britain by citing clauses in its UK contracts that prevent exports of the vaccine it developed with Oxford University.

The UK government has denied export curbs and is seeking extra doses from a factory in the Netherlands run by AstraZeneca's sub-contractor Halix. The EU is now blocking exports from that plant.

The U.S. government has told Brussels it will not export doses to Europe until its vaccine rollout is completed.

UNDER-DELIVERING

With the pandemic still raging across the continent, the AstraZeneca vaccine was seen as a central part of Europe's immunisation campaign and a way to send coronavirus shots to poorer countries because of its simple storage requirements.

But cuts and delays in deliveries have disrupted the inoculation campaign in the EU, which trails behind Britain, the United States and Israel on vaccinations.

By the end of March, AstraZeneca had delivered only a quarter of what it had committed to the EU. The company has said it plans to ship a total of 100 million doses to the bloc by the end of June, instead of 300 million foreseen in the contract.

Under Britain's 100-million-dose contract, AstraZeneca was supposed to have delivered 30 million by September 2020, but it had only supplied about five million by the end of last year. One million doses came from EU factories, officials have said.

AstraZeneca has blamed production problems for the delays.

In court, the first session ended in just over an hour and the parties agreed to hold two hearings on May 26. The EU lawyers asked for a decision before the end of June to make sure missing doses could be delivered in a timely fashion.

An EU official told Reuters earlier this week the EU could settle for 130 million doses by the end of June.

If no other hearing is necessary, a decision could be made in the weeks following the May 26 hearings.

"AstraZeneca deeply regrets the decision of the European Commission to start this legal action," company lawyer Hakim Boularbah told journalists after the hearing. "We hope to resolve this dispute as soon as possible."

EU demands immediate access to UK-made vaccines in AstraZeneca legal battle
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email